8-K: FMC Q3 Results: India Sale Hits Revenue, Outlook Cut

FMC Corporation reported a significant third-quarter revenue decline and net loss, primarily due to charges related to its India business sale, leading to lowered full-year guidance and a dividend reduction.

Summary

• Third quarter 2025 revenue was $542 million, a 49% decrease compared to Q3 2024, largely due to one-time commercial actions in India to position the business for sale.
• Excluding India, Q3 revenue was $961 million, down 10% versus Q3 2024, with an 11% organic decline driven by lower pricing.
• GAAP net loss for Q3 2025 was $569 million, or $4.52 per diluted share, primarily due to $510 million in charges and write-downs related to the India commercial business held for sale.
• Adjusted EBITDA increased 17% to $236 million, and Adjusted EPS rose 30% to $0.89, mainly due to higher Adjusted EBITDA.
• Full-year 2025 revenue outlook was lowered to $3.92 billion to $4.02 billion, a 7% decline at the midpoint versus 2024.
• Full-year Adjusted EBITDA outlook was lowered to $830 million to $870 million, a 6% decline at the midpoint versus 2024.
• Full-year Adjusted EPS outlook was lowered to $2.92 to $3.14, a 13% decline at the midpoint to prior year.
• Free cash flow forecast for the full year was lowered to negative $200 million to $0, reflecting a $714 million decline at the midpoint from prior year.
• The quarterly dividend was reduced to $0.08 per share to prioritize debt reduction.
• FMC is redesigning its manufacturing footprint to exit high-cost plants and implementing cost reduction initiatives in Asia following the India sale.

Sentiment

Score: 2

Explanation: The filing indicates significant negative financial performance, including a large GAAP net loss, substantial revenue decline, and lowered full-year guidance. The dividend reduction and asset write-down further underscore a challenging period for the company, despite some positive adjusted metrics.

Positives

• Adjusted EBITDA increased 17% to $236 million in Q3 2025 compared to Q3 2024.
• Adjusted earnings per diluted share increased 30% to $0.89 in Q3 2025 compared to Q3 2024.
• Overall company volume increased 2% in Q3 2025, driven by mid-single digit growth in the company's growth portfolio.
• Sales in North America improved 4% year-over-year, driven by higher volume in the growth portfolio and branded Rynaxypyr active.
• Sales in EMEA increased 11% (7% excluding foreign currency) due to higher volumes in the growth portfolio and the launch of Isoflex active in Great Britain.
• The sales process for the India commercial business is progressing well with strong interest.

Negatives

• Total revenue declined 49% to $542 million in Q3 2025 compared to Q3 2024.
• Consolidated GAAP net loss was $569 million, a decline of $634 million versus Q3 2024.
• Consolidated GAAP net loss per diluted share was $4.52, down $5.04 versus Q3 2024.
• Revenue excluding India declined 10% (11% organically) due to lower pricing and increased generic competition.
• The India commercial business, with a carrying value of approximately $960 million, was written down to an estimated fair value of $450 million, resulting in $510 million of charges and write-downs in Q3 2025.
• Latin America sales were 8% lower than prior year (9% lower excluding currency impacts) due to increased generic pressure, lower pricing, lower volume, and customer liquidity/credit constraints in Brazil and Argentina.
• Asia sales, excluding India, declined 47% (46% excluding currency impacts) due to the removal of India, lower volumes, and lower price from increased generic competition.
• GAAP cash from operations was negative $184 million, a decline of $344 million versus 2024, largely due to working capital pressures.
• Free cash flow was negative $233 million, a decline of $365 million versus Q3 2024.
• Full-year 2025 revenue, Adjusted EBITDA, and Adjusted EPS outlooks were all lowered.
• The quarterly dividend was reduced to $0.08 per share.

Risks

• Increased competitive pressure from generics in Latin America and Asia could continue to impact pricing and volume.
• Low customer liquidity and credit constraints in key markets like Brazil and Argentina pose a risk to growth.
• Working capital pressures contributed to negative cash from operations and free cash flow.
• The ongoing sale of the India commercial business involves significant one-time commercial actions and a substantial write-down, with potential for further adjustments.
• The company's manufacturing footprint redesign and cost reduction initiatives carry execution risks and potential for further restructuring charges.
• Foreign currency fluctuations, despite being a tailwind in Q3, can pose future headwinds.

Future Outlook

FMC Corporation has lowered its full-year 2025 guidance across revenue, Adjusted EBITDA, Adjusted EPS, and free cash flow. For the fourth quarter, excluding India, revenue is expected to be $1.12 billion to $1.22 billion, a 4% decline at the midpoint versus Q4 2024. Adjusted EBITDA is forecasted to be $265 million to $305 million, a 16% decline at the midpoint, and Adjusted EPS is expected to be $1.14 to $1.36, a 30% decrease at the midpoint. The company anticipates volume growth from new products and an additional route to market in Brazil, but expects mid-to-high-single digit pricing headwinds due to generic pressure and cost-plus contract adjustments.

Management Comments

• "Third quarter sales were down 49 percent versus prior year largely due to India actions. However, on a like-for-like basis, sales were down 4 percent, excluding India in both periods."
• "Our results reflect the challenges we're facing, most prominently in Latin America. Despite this, our new active ingredients nearly doubled in the quarter and remain central to our strategy."
• "Over the last 18 months, we have made hard decisions to position the business for recovery and to streamline our operating model. Now, to improve the competitiveness of our legacy products, we are confronting cost head-on by re-aligning our manufacturing footprint and reducing the size of our Asia operations following the India exit. To further prioritize cash generation and debt reduction, the FMC Board of Directors has made the decision to reduce the dividend. We continue to believe our pipeline of new active ingredients is our true differentiator and it remains the growth engine of the company."

Industry Context

The agricultural sciences industry is experiencing increased competitive pressure, particularly from generics in regions like Latin America and Asia, leading to pricing declines. Economic challenges, such as low customer liquidity and credit constraints in markets like Brazil and Argentina, are further inhibiting growth. Companies like FMC are responding by divesting underperforming assets (e.g., India business), optimizing manufacturing footprints, and focusing on innovative new active ingredients to differentiate themselves and compete against lower-cost alternatives.

Corporate Governance

Stakeholder Impact

• Shareholders: Will experience a significant reduction in dividend payments and a substantial GAAP net loss, alongside lowered future earnings and cash flow expectations. The write-down of the India business also impacts equity.
• Employees: May be affected by the redesign of the manufacturing footprint, including potential plant exits and transitions, as well as cost reduction initiatives in Asia, which could lead to job reassignments or reductions.
• Customers: In Latin America, customers face credit constraints, and in India, commercial actions included product returns and pricing changes, which could impact customer relationships and supply dynamics.
• Creditors: The company is prioritizing debt reduction, which could be a positive signal for creditors regarding the company's commitment to financial health.

Next Steps

• Continue the sales process for the India commercial business, expected to conclude within the next twelve months.
• Redesign the manufacturing footprint by exiting high-cost active ingredient and formulation plants and transitioning production to lower-cost sources.
• Implement cost reduction initiatives in Asia to adjust for the reduced size of the region's business following the India sale.
• Focus on new active ingredients as the growth engine of the company.

Key Dates

Recommendation

The filing reveals a deeply concerning financial picture for FMC Corporation, marked by a massive GAAP net loss, a nearly 50% revenue decline, and a significant write-down of its India business. The lowered full-year guidance across all key metrics (revenue, EBITDA, EPS, and free cash flow, which is now projected to be negative) indicates a deteriorating outlook. The dividend cut, a clear signal of financial stress and a shift to debt reduction, further reinforces the negative sentiment. While adjusted EBITDA and EPS showed increases, these are overshadowed by the GAAP losses and the fundamental challenges in key markets like Latin America and Asia due to generic competition and economic headwinds. A seasoned investor would likely view these results and outlook as a strong sell signal, anticipating continued pressure on the stock price.

Keywords

FMC Corporation, Q3 2025 Earnings, Agricultural Sciences, Crop Protection, India Business Sale, Adjusted EBITDA, Adjusted EPS, Revenue Decline, Dividend Reduction, Generic Competition, Manufacturing Restructuring, Free Cash Flow, Working Capital